期刊文献+

Toll样受体在动脉粥样硬化中作用的研究进展 被引量:4

The research progress of Toll like receptors in atherosclerosis
原文传递
导出
摘要 Toll样受体(TLRs)是模式识别受体(PRRs)之一,其因胞外段与一种果蝇蛋白Toll同源而得名。TLRs广泛分布于巨噬细胞、树突样细胞、T细胞、B细胞等免疫细胞,还存在于一些组织细胞巾,如心肌细胞等。TLRs不仅可诱导固有免疫反应作为机体对病原微生物的第一道防线,也可通过激活抗原递呈细胞诱导适应性免疫反应。大量证据表明,TLRs除参与宿主抵抗病原菌的侵害之外,还在非感染性组织损伤中起作用,例如心肌缺血再灌注损伤,缺血后心肌重塑和动脉粥样硬化等疾病。故了解TLRs信号通路及其在心血管疾病中的作用可帮助我们确定干预心血管疾病的潜在靶点,且有重要的临床应用价值。 Toll like receptors (TLRs) , which are named after the extracellular domain homologous to a Drosophila protein Toll, belong to the family of pattern recognition receptors (PRRs). TLRs widely express in macrophages, dendritic cells, T cells, B cells and other immune cells. They are also detected on many other tis- sue cells, for example myocardial cells. TLRs can not only trigger innate immune response as the body' s first line of defense against pathogenic microorganisms, but also induce adaptive immune response through the acti- vation of antigen presenting cells. In addition to participating in the host defense against infectious pathogens, accumulating evidence suggests that TLRs still play a role in the non-infectious tissue injury, such as myocardi- al ischemia and reperfusion injury, ischemic myocardial remodeling, atherosclerosis and other diseases. Thus, understanding TLRs signaling pathways and their role in cardiovascular diseases can help us to identify potential targets for the intervention cardiovascular diseases.
作者 王杨 关秀茹
出处 《国际免疫学杂志》 CAS 2013年第4期253-255,259,共4页 International Journal of Immunology
基金 国家自然科学基金主任基金(81241006)
关键词 TOLL样受体 固有免疫 动脉粥样硬化 巨噬细胞 Toll like receptors Innate immune Atherosclerosis Macrophage
作者简介 通信作者:关秀茹,E-mail:guanxiuru0451@yahoo.com.cn
  • 相关文献

参考文献2

二级参考文献34

  • 1Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation[J].Nat Rev Immunol, 2008,8 : 958-969.
  • 2Stein M, Keshav S, Harris N, et al. Interleukin 4 potently enhances murine maerophage mannose receptor activity: a marker of alternative immunologic macrophage activation[J].J Exp Med,1992, 176:287-292.
  • 3Gordon S. Alternative activation of macrophages[J]. Nat Rev Immunol, 2003,3:23-35.
  • 4Martinez FO, Helming L, Gordon S. Alternative activation of macrophages:an immunologic functional perspective[J].Annu Rev Immunol, 2009,27:451-483.
  • 5Timmer AM, Nizet V. IKKI3/NF-κB and the miscreant macrophage[J]. J Exp Med,2008, 205:1655-1659.
  • 6Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions[J]. Immunity, 2010,32:593- 604.
  • 7Liu Y, Stewart KN, Bishop E, et al. Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo[J]. J Immunol, 2008, 180:6270-6278.
  • 8Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance [J].Nature, 2007,447 :1116- 1120.
  • 9Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1alpha is essential for myeloid cell mediated inflammation [J]. Cell, 2003,113:419.
  • 10Ishii M, Wen H, Corsa CA, et al. Epigenetic regulation of the alternatively activated macrophage phenotype[J]. Blood, 2009 , 114:3244-3254.

共引文献53

同被引文献43

  • 1WANG YaYa1,ZHANG Peng2,LIU YingFang2 & CHENG GenHong1 1 Department of Microbiology,Immunology & Molecular Genetics,University of California Los Angeles,609 Charles E.Young Drive East,Los Angeles,California 90095,USA,2 National Laboratory of Biomacromolecules,Institute of Biophysics,Chinese Academy of Sciences,Beijing 100101,China.TRAF-mediated regulation of immune and inflammatory responses[J].Science China(Life Sciences),2010,53(2):159-168. 被引量:23
  • 2Park SW , Kim M, Brown KM. Paneth cell-derived interleukin -17 A causes multiorgan dysfunction after hepatic ischemia and reperfusion injuryJ J]: Hepatology,2011 ,53(5) :1662-1675.
  • 3Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damageJ J}. Nat Rev Immunol,2010,lO(l2) :826-837.
  • 4Weyker PD, Webb CA, Kiamanesh D. Lung ischemia reperfusion injury: a bench-to-bedside review[J]. Semin Cardiothorac Vase Anesth,2013,17(1) :2843.
  • 5Yip HK, Chang YC. Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury[J].J Pineal Res,2013,54(2) :207-22l.
  • 6Souidi N, Stolk M, Seifert M. Ischemia-reperfusion injury: beneficial effects of mesenchymal stromal cells[J]. CUff Opin Organ Transplant,2013, 18 ( 1 ) :3443.
  • 7Den Hengst WA, GielisJF. Lung ischemia-reperfusion injury: a molecular and clinical view on a complex pathophysiological process[J]. AmJ Physiol Heart Circ Physiol, 2010, 299 ( 5 ) : HI283-1299.
  • 8Manning E,Pham S,Li S. Interleukin-lO delivery via mesenchymal stem cells: a novel gene therapy approach to prevent lung ischemiareperfusion injury[J]. Hum Gene Ther,2010,21 (6) :713-727.
  • 9Svobodova E, Krulova M, Zajicova A. The role of mouse mesenchymal stem cells in differentiation of naive T -cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population[J]. Stem Cells Dev,2012,21(6) :901-910.
  • 10De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A. Immunosuppressive properties of mesenchymal stem cells: advances and applications[J]. CUff Mol Med,2012,12(5) :574-59l.

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部